Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda Discontinues Development of Prostate Cancer Vaccine GVAX
November 3, 2008
- BI to Enter Market for Antidiabetics with BI 1356: Dr Barner
November 3, 2008
- Banyu to Close Tsukuba Research Institute
November 3, 2008
- Bio Japan 2008
October 27, 2008
- BP Levels, Hypotensive Targets at Initiation of Treatment Dropping: CareNet Survey
October 27, 2008
- NEW PRODUCTS
October 27, 2008
- AZ Strengthens Its Biopharmaceuticals R&D Pipeline: Mr Brennan
October 27, 2008
- Kitasato Univ.-Harvard School of Public Health Symposium
October 27, 2008
- R&D NEWS IN BRIEF
October 27, 2008
- Sports Improve Symptoms of Schizophrenia
October 27, 2008
- Korosho to Ally with Authorities from Other Countries to Eliminate Drug Lag
October 27, 2008
- Merck Serono, Bristol-Myers to Copromote Erbitux with 300 MRs
October 27, 2008
- SJP Seminar Focuses on Pharmacovigilance
October 27, 2008
- Kowa Obtains Global License for DPP-4 Inhibitor from Sanwa Kagaku
October 27, 2008
- REGULATORY NEWS IN BRIEF
October 27, 2008
- Meiji Seika to Develop Biocodex's Stiripentol for SMEI
October 27, 2008
- Korosho Plans to Expand Range of OTC Drugs: Mr Kishida
October 27, 2008
- Ajinomoto Licenses MoviPrep from Norgine
October 27, 2008
- JACDS Supports Korosho's Draft Ordinance Regarding Online Sales of OTC Drugs
October 27, 2008
- Fuji Biomedix Applies for Civil Rehabilitation, Toho to Acquire Its Dispensing Pharmacy Div.
October 27, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…